Genetic Determinants of the Response to Salbutamol Among Asthma Patients

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2008 by Hadassah Medical Organization.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Hadassah Medical Organization
ClinicalTrials.gov Identifier:
NCT00162396
First received: September 11, 2005
Last updated: October 28, 2008
Last verified: October 2008

September 11, 2005
October 28, 2008
August 1999
Not Provided
  • Change in lung function tests after salbutamol inhalation
  • Change in blood pressure and pulse after salbutamol inhalation
Same as current
Complete list of historical versions of study NCT00162396 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Genetic Determinants of the Response to Salbutamol Among Asthma Patients
Evaluation of Genetic Factors That May Account for Variability in the Response to Salbutamol Among Patients Suffering From Asthma

The response to salbutamol varies greatly among individuals. Data from previous studies indicate that some of the variability is accounted for by genetic polymorphisms in the gene encoding for the adrenoceptor subtype β2. The current study was designed to evaluate variability in the response to salbutamol among recently diagnosed patients who have not been treated by β2 agonists or corticosteroids.

Lung function tests will be performed prior to and following a single dose administration of salbutamol through inhalation. Additional pharmacodynamic indices will be monitored including pulse and blood pressure. Three samples of plasma will be drawn for the evaluation of salbutamol plasma concentration.

Not Provided
Interventional
Not Provided
Allocation: Non-Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Asthma
Drug: Albuterol
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
150
Not Provided
Not Provided

Inclusion Criteria:

  • 18 years and older
  • Recently diagnosed as asthmatic

Exclusion Criteria:

  • Current treatment by β2 agonist
  • Current treatment by corticosteroids
  • Acute asthma attack
Both
18 Years and older
No
Contact: Yoseph Caraco, MD 00 972 2 6778584 caraco@hadassah.org.il
Israel
 
NCT00162396
yc195511-HMO-CTIL
Not Provided
Not Provided
Hadassah Medical Organization
Not Provided
Principal Investigator: Yoseph Caraco, MD Hadassah Medical Organization
Hadassah Medical Organization
October 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP